Parallel Session 3411

Tau Disorders – PSP and CBD: Homogeneity and Heterogeneity

Tuesday, October 6, 2026
14:30 - 16:00 | Conference Room E6, Level 3

In this session, the faculty will demonstrate the homogeneity and heterogeneity of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) from neuropathological, clinical, and biomarker perspectives. Attendees will gain insights into the core and variable pathological features of these tauopathies, examine the diverse clinical phenotypes and their implications for diagnosis and treatment, and evaluate the role of advanced neuroimaging and emerging biomarkers in enhancing diagnostic precision and guiding therapeutic trials.

Chairs:

Huw Morris, United Kingdom
Jinyoung Youn, Korea

Presenters:

Homogeneity and Heterogeneity in Neuropathology of PSP and CBD
Hidetomo Tanaka, Canada

Clinical Phenotypic Variability Associated with PSP and CBD Pathology
Jacy Parmera, Brazil

Neuroimaging and Biomarkers in PSP and CBD: Paving the Path for Therapy Trials
Carla Palleis, Germany

CSPC Liaison(s):

Gabor Kovacs, Canada

Learning Objectives

At the conclusion of this session, participants should be better able to:

1. Analyze the neuropathological variability within and between PSP and CBD subtypes
2. Recognize the spectrum of clinical phenotypes associated with PSP and CBD type pathology
3. Identify and evaluate emerging biomarkers relevant to PSP and CBD

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Health Professional (non-physician)
Industry

Education Level

Advanced / Expert
Intermediate / Experienced